Cargos activos de Howard Davis
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Director/Miembro de la Junta | 11/08/2022 | - |
| Director Ejecutivo | 11/08/2022 | - |
Historial de carrera de Howard Davis
Antiguos cargos conocidos de Howard Davis.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| THIRD HARMONIC BIO, INC. | Director de Operaciones | - | - |
Estadísticas
Internacional
| Estados Unidos | 2 |
| Reino Unido | 2 |
Operativa
| Chief Operating Officer | 1 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectorial
| Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| THIRD HARMONIC BIO, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Howard Davis
- Experiencia
